1. Beer TM, Myrthue A, Eilers KM. Rationale for the development and current status of calcitriol in androgen-independent prostate cancer. World J Urol. 2005;23:28–32.
2. Beer TM, Javle MM, et al. Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancer. Cancer Chemother Pharmacol. 2007a;59(5):581–7.
3. Beer TM, Ryan CW, et al. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen independent prostate cancer: a report from the ASCENT investigators. J Clin Oncol. 2007b;25(6):669–74.
4. Carlberg C, Dunlop TW. The impact of chromatin organization of vitamin D target genes. Anticancer Res. 2006;26(4A):2637–45.
5. Chaudhry M, Sundaram S, et al. The vitamin D3 analog, ILX-23-7553, enhances the response to adriamycin and irradiation in MCF-7 breast tumor cells. Cancer Chemother Pharmacol. 2001;47(5):429–36.